Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta-analysis

Human Psychopharmacology

Volumn , Issue , 2016, Pages 268-285

  Dundar, Yenal ^a,b   Greenhalgh, Janette ^a   Richardson, Marty ^a   Dwan, Kerry ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b MERSEY CARE NHS TRUST   (United Kingdom)

Author keywords

agitation; antipsychotic drugs; benzodiazepines; bipolar disorder; schizophrenia; systematic review

Indexed keywords

ARIPIPRAZOLE; CLONAZEPAM; HALOPERIDOL; LORAZEPAM; LOXAPINE; OLANZAPINE; RISPERIDONE;

AGITATION; ARTICLE; BIPOLAR DISORDER; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; HUMAN; META ANALYSIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

EID: 84977629223     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2535     Document Type: Article

References (42)

1. DSM IV: American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders: 4th ed., Text Revision (DSM-IV-TR). American Psychiatric Press Inc: Washington, DC.
2. Ahmed U, Jones H, Adams CE. 2010. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database Syst Rev 4: Cd007445.
3. Allen MH. 2000. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 61(Suppl. 14): 11–20.
4. Allen MH, Feifel D, Lesem MD, et al. 2011. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 72: 1313–1321.
5. Andrezina R, Josiassen RC, Marcus RN, et al. 2006. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 188: 281–292.
6. Bhandari M, Busse JW, Jackowski D, et al. 2004. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 170: 477–80.
7. Breier A, Meehan K, Birkett M, et al. 2002. A double-blind, placebo-controlled dose–response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 59: 441–448.
8. Brown S. 2011. Treatment of acute psychotic agitation: gaps in the evidence base. Commentary on Management of Acute Agitation on Psychosis. Adv Psychiatr Treat 17: 101–3.
9. Centorrino F, Meyers AL, Ahl J, et al. 2007. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder. Hum Psychopharm Clin Exp 22: 455–462.
10. Centre for Reviews and Dissemination. 2009. Systematic Reviews: CRDs guidance for undertaking reviews in healthcare [cited 2011 March]; Available from: http://www.york.ac.uk/inst/crd/darefaq.htm.
11. Citrome L. 2004a. New treatments for agitation. Psychiatric Quart 75: 197–213.
12. Cooper JE (Editor), World Health Organization Geneva. 1994. Pocket guide to the ICD-10 classification of mental and behavioural disorders: with glossary and diagnostic criteria for research: ICD-10: DCR-10. Edinburgh: Churchill Livingstone, 1994.
13. Currier GW, Chou JC, Feifel D, et al. 2004. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 65: 386–394.
14. Fang M, Chen H, Li LH, et al. 2012. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. Int Clin Psychopharmacol 27: 107–113.
15. Flacco ME, Manzoli L, Boccia S, et al. n.d. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J0 Clin Epidemiol 68: 811–820.
16. Gillies D, Sampson S, Beck A, Rathbone J. 2013. Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev 4: Cd003079.
17. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. 2003. Measuring inconsistency in meta-analysis. Br Med J 327: 557–60.
18. Hsu WY, Huang SS, Lee BS, Chiu NY. 2010. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol 30: 230–234.
19. Hwang TJ, Chen Y, Lc H, Huang G, Hg H. 2012. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam in the treatment of acute agitation in schizophrenia. J Eur College Neuropsychopharm 22: S333.
20. Katagiri H, Fujikoshi S, Suzuki T, et al. 2013. A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation. BMC Psychiatry 13: 1–8.
21. Kinon BJ, Ahl J, Rotelli MD, Mcmullen E. 2004. Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. Am J Emergen Med 22: 181–6.
22. Kwentus J, Riesenberg RA, Marandi M, et al. 2012. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord 14: 31–40.
23. Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. 2011. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 198: 51–58.
24. Lim HK, Kim JJ, Pae CU, Lee CU, Lee C, Paik IH. 2010. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. Neuropsychobiology 62: 81–86.
25. Lindenmayer JP. 2000. The pathophysiology of agitation. J Clin Psychiatry 61(Suppl 14): 5–10.
26. Meehan K, Zhang F, David S, et al. 2001. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 21: 389–397.
27. Moher D, Liberati A, Tetzlaff J, Altman D. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 21;6(7): e1000097. doi: 10.1371/journal.pmed.1000097
28. Montoya A, Valladares A, Lizan L, San L, Escobar R, Paz S. 2011. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes 9: 18.
29. National Institute for Health and Care Excellence. 2014a. CG185: Bipolar Disorder: The Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. NICE: London.
30. National Institute for Health and Care Excellence. 2014b. CG 178: Psychosis and Schizophrenia in Adults: Treatment and Management. NICE: London.
31. National Institute for Health and Clinical Excellence. CG25: Violence. The Short-Term Management of Disturbed/Violent Behaviour in in-Patient Psychiatric Settings and Emergency Departments. London: NICE; 2005 [cited 2012 January]; Available from: http://www.nice.org.uk/CG25.
32. National Institute for Health and Clinical Excellence. Draft Scope for the Proposed Appraisal of Loxapine Inhalation for the Treatment of Agitation in People With Schizophrenia or Bipolar Disorder. London: NICE; 2011 [cited 2012 January]; Available from: http://www.nice.org.uk/ourguidance/niceguidancebytype/technologyappraisals/proposedappraisals/nowave.jsp?domedia=1&mid=02BF16A0-19B9-E0B5-D43FC671ABF1E3EE.
33. Nordstrom K. 2009. Inhaled loxapine for acute agitation in schizophrenia and bipolar disorder. Future Neurol 4: 539–545.
34. Powney MJ, Adams CE, Jones H. 2012. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 11: Cd009377.
35. Rochon PA, Gurwitz J, Rw S, et al. 1994. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 154: 157–163.
36. Sachs GS. 2006. A review of agitation in mental illness: burden of illness and underlying pathology. J Clin Psychiatry 67: 5–12.
37. Schleifer JJ. 2011. Management of acute agitation in psychosis: an evidence-based approach in the USA. Adv Psychiatr Treat 17: 91–100.
38. The Nordic Cochrane Centre (2014) Review Manager (RevMan),. IN The Cochrane Collaboration (Ed.) 5.3 ed. Copenhagen.
39. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, Mcquade RD, Oren DA. 2007. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 68: 111–119.
40. Wright P, Birkett M, David SR, et al. 2001. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 158: 1149–1151.
41. Zhang H, Wang G, Zhao J, et al. 2013. Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. J Clin Psychopharmacol 33: 178–85.
42. Zimbroff DL, Marcus RN, Manos G, et al. 2007. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 27: 171–176.